🧾 What This Document Is

This is an earnings release from Ensysce Biosciences, announced on March 30, 2026. It’s like a company’s quarterly report card, showing how they did financially and operationally for the final three months (Q4) and all of 2025. It also updates investors on the progress of their key drug development programs.

🏢 What The Company Does

👉 In simple terms, Ensysce is a biotech company trying to invent safer opioid painkillers. Their goal is to create strong pain medication that’s much harder to abuse or accidentally overdose on, using two special technologies:

• TAAP™: A "key" that only unlocks the drug in your intestines, making it useless if snorted or injected.
• MPAR®: A built-in "chemical off-switch" that stops the drug from working if someone swallows too many pills at once.

They're a clinical-stage company, meaning they're still spending money on research and trials to prove their drugs work and are safe, and aren't selling any products yet.

💰 Financial Highlights

The company is burning cash to fund its research, which is typical for a biotech at this stage.

• 💵 Cash on Hand: They ended 2025 with $4.3 million in cash, up from $3.5 million at the end of 2024. This is their runway to fund operations.
• 📉 Net Loss: They lost $10.2 million in 2025, more than the $8.0 million loss in 2024. This was mainly due to higher spending on their clinical trials.
• 🔬 Research & Development (R&D) Spend: Their biggest cost, R&D expenses jumped to $10.4 million in 2025 (from $7.2 million in 2024) because of increased clinical trial activity.
• 🏛️ Grant Funding: They received $5.1 million in federal grants (from agencies like NIDA) to help fund specific research projects.

👉 Why it matters: Their losses are growing as they advance their most promising drugs into expensive late-stage trials. Their survival depends on securing more funding.

🚀 Key Moves in 2025

The company hit several important milestones that move their drugs closer to the market.

• Started a Major Trial: They began their Phase 3 trial (PF614-301) for their lead drug, PF614. This is the last major study needed before asking the FDA for approval.
• Got FDA Feedback: They had positive discussions with the FDA about the development path for their overdose-protected drug (PF614-MPAR), including the possibility of a faster approval pathway.
• Strengthened Patents: A new U.S. patent was allowed for their MPAR® technology, extending their intellectual property protection until 2042. They also got good news from the European patent office for a different application.

📦 Financial Position

Looking at their balance sheet gives a snapshot of their health.

• Total Assets: $7.5 million, mostly made up of cash ($4.3 million) and prepaid expenses.
• Total Liabilities: $4.6 million, primarily money they owe to vendors (accounts payable).
• Stockholders' Equity: $2.9 million. This is the net worth belonging to shareholders. It decreased from 2024 because of the year's losses.

👉 Why it matters: Their liabilities have grown significantly, and their cash cushion is modest. They will likely need to raise more money soon to fund the expensive Phase 3 trials and operations.

🔮 What's Next

The company’s roadmap is focused on pushing their lead programs forward.

• Advance PF614: Continue enrolling patients in the Phase 3 trial and work toward regulatory submission.
• Develop PF614-MPAR: Follow the accelerated path supported by the FDA's Breakthrough Therapy designation.
• Expand the Pipeline: Move forward with their new candidate PF9001 for opioid use disorder (OUD) and explore using their tech for ADHD treatments.
• Seek Funding: They will need to secure additional capital to fund these activities.

⚖️ Big Picture

• 👍 Strengths: Their drug platforms (TAAP™ and MPAR®) address a critical public health need (opioid abuse) with a novel approach. They have strong grant funding and positive FDA feedback, which validates their science.
• ⚠️ Risks: They are not yet profitable and have a limited cash runway. Biotech drug development is high-risk and expensive—any trial delays or failures could be devastating. The competitive landscape for pain management is also tough.

🧠 The Analogy

Ensysce is like a startup building a "smart car" for pain medication. Their TAAP™ is like an engine that only starts with a specific fuel (digestive enzymes), making it useless to try and hotwire. Their MPAR® is like a speed governor that automatically kicks in if the car detects someone is trying to floor it dangerously. They've now finished building the prototype (preclinical work) and have started the official, long road test (Phase 3 trial) to prove it's safe and effective before they can sell it.

📇 Key Contacts & People

• Lynn Kirkpatrick, Ph.D. - Chief Executive Officer
• Shannon Devine - MZ North America (Investor Relations)
• Phone: (858) 263-4196
• IR Main: 203-741-8811
• IR Email: [email protected]

🧩 Final Takeaway

Ensysce spent 2025 advancing its innovative abuse-resistant opioid drugs into late-stage trials, but this progress came with increased losses and cash burn. Their next 12-18 months are critical as they execute expensive Phase 3 trials and will likely need to raise more capital to succeed.